Neutrophil activation markers can predict rheumatoid arthritis treatment response to the Janus Kinase 1/2 inhibitor baricitinib

IF 11.4 1区医学 Q1 RHEUMATOLOGY

Arthritis & Rheumatology Pub Date : 2024-10-21 DOI:10.1002/art.43042

Runa Kuley, Bhargavi Duvvuri, Sabeeha Hasnain, Ernst R. Dow, Alisa E. Koch, Richard E. Higgs, Venkatesh Krishnan, Christian Lood

引用次数: 0

Abstract

Neutrophils play an important role in regulating immune and inflammatory responses in rheumatoid arthritis (RA). We assessed whether baricitinib, a JAK1/JAK2 inhibitor, could reduce neutrophil activation, and whether a neutrophil activation score could predict treatment response.

查看原文本刊更多论文

中性粒细胞活化标记物可预测类风湿性关节炎患者对 Janus 激酶 1/2抑制剂巴利替尼的治疗反应

中性粒细胞在调节类风湿性关节炎（RA）的免疫和炎症反应中发挥着重要作用。我们评估了JAK1/JAK2抑制剂巴利昔尼能否降低中性粒细胞活化，以及中性粒细胞活化评分能否预测治疗反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Arthritis & Rheumatology RHEUMATOLOGY-

CiteScore

20.90

自引率

3.00%

发文量

371

期刊介绍： Arthritis & Rheumatology is the official journal of the American College of Rheumatology and focuses on the natural history, pathophysiology, treatment, and outcome of rheumatic diseases. It is a peer-reviewed publication that aims to provide the highest quality basic and clinical research in this field. The journal covers a wide range of investigative areas and also includes review articles, editorials, and educational material for researchers and clinicians. Being recognized as a leading research journal in rheumatology, Arthritis & Rheumatology serves the global community of rheumatology investigators and clinicians.